|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM193724499 |
| 003 |
DE-627 |
| 005 |
20231223195310.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2009.11.011
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0646.xml
|
| 035 |
|
|
|a (DE-627)NLM193724499
|
| 035 |
|
|
|a (NLM)20006940
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Park, Youn-Hee
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Effect of in vitroexpanded CD4(+)CD25(+)Foxp3(+) regulatory T cell therapy combined with lymphodepletion in murine skin allotransplantation
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 22.04.2010
|
| 500 |
|
|
|a Date Revised 18.11.2010
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2009 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a A promising approach for preventing allograft rejection involves shifting the balance between cytopathic and regulatory T cells to dominance of the latter cell type. Nonspecific lymphodepletion was conducted by administration of depleting anti-CD4 and anti-CD8 antibodies to reduce effector T cells and adoptive transfer of ex vivo-expanded host Treg cells by stimulation with donor dendritic cells to augment the Treg cell compartment. Evaluation of an MHC-mismatched skin allograft model revealed that combined therapy with these two protocols consistently induced modest prolongation of allograft survival, although all skin grafts were eventually rejected. The administration of IL-2/anti-IL-2 complexes significantly improved the efficacy of combination therapy via promoting the expansion of adoptively transferred Treg cells as well as endogenous recipient Treg cells. We conclude that Treg cell therapy combined with lymphodepletion is of practical benefit for the control of allograft rejection, but requires supplementary measures to promote immune tolerance
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a FOXP3 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Forkhead Transcription Factors
|2 NLM
|
| 650 |
|
7 |
|a IL2RA protein, human
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-2 Receptor alpha Subunit
|2 NLM
|
| 700 |
1 |
|
|a Koo, Sun-Kyung
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Youngji
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Hye-Mi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Joe, In-Yi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Chan-Sik
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Song-Cheol
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Han, Duck-Jong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lim, Dong-Gyun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 135(2010), 1 vom: 21. Apr., Seite 43-54
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:135
|g year:2010
|g number:1
|g day:21
|g month:04
|g pages:43-54
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2009.11.011
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 135
|j 2010
|e 1
|b 21
|c 04
|h 43-54
|